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assessed using Cronbach’s alpha and intra-class correlation. RESULTS: The mean age 
was 76.3 (8.9) years, majority of the subjects were female (55.1%), residing in the 
United States (77.5%) and Caucasian (92.8%). The mean utility value calculated with 
the VFQ-UI was 0.68 (0.11), compared to the EQ-5D: 0.88 (0.12), HUI2: 0.81 (0.13), 
and HUI3: 0.73 (0.22). The VFQ-UI is associated with HUI2 (r = 0.22, p < 0.05) but 
not signiﬁcantly associated with the EQ-5D or the HUI3. There was no signiﬁcance 
in the correlation between VFQ-UI and visual acuity in the study eye. The VFQ-UI 
varied by known groups using a combination of study and fellow eye visual acuity; 
the more impaired visual acuity the lower the utility value (more disability in visual 
functioning). Internal consistency reliability for the VFQ-UI was 0.76 and the intra-
class correlation was 0.84. CONCLUSIONS: Utility values calculated from the 
VFQ-UI demonstrated greater visual functioning impairment compared to the HUI 
and EQ-5D. The VFQ-UI showed good convergent validity with the HUI2, good 
discriminant validity with visual acuity known groups and good internal consistency 
and test-retest reliability in individuals with AMD.
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OBJECTIVES: The Eyelash Satisfaction Questionnaire (ESQ), a static measure, has 
been previously validated for the assessment of eyelash-speciﬁc patient-reported out-
comes (PROs) in subjects receiving a therapeutic treatment for hypotrichosis of eye-
lashes. The current study aimed to validate a similar questionnaire, the Eyelash 
Satisfaction Follow-up Questionnaire (ESFQ), a 39-item dynamic measure designed 
speciﬁcally to self-assess eyelash-speciﬁc PROs. METHODS: The ESFQ was initially 
examined in a 909-person validation sample consisting of online respondents. Conﬁr-
matory factor analysis (CFA) was initially used to test the measurement structure of 
the questionnaire. Item- and scale-level psychometric properties such as item-total 
correlations, internal consistency, and convergent and discriminant validities were 
reviewed. The ESFQ was then used in a clinical population receiving bimatoprost 
ophthalmic solution 0.03%, a product that improves eyelash prominence, during a 
16-week randomized, controlled, masked, clinical trial. RESULTS: Initial CFA results 
revealed a “good ﬁt” based on hypothesized similarity with the factor structure identi-
ﬁed in the ESQ. A model using 9 indicators (3 per factor), similar to the structure of 
the ESQ, was chosen as the optimal method. The ﬁnal model showed good internal 
consistency along with convergent and discriminant validities. However, the alpha-
removed statistic for the length, fullness, and overall satisfaction (LFOS) construct 
showed a signiﬁcant increase in scale consistency with the removal of item 8 (Com-
pared to your ﬁrst visit, overall, how satisﬁed are you with your eyelashes now?). 
Despite this, the model structure was retained to better facilitate comparisons between 
the ESQ and ESFQ and to provide sufﬁcient measures to properly evaluate the con-
struct. CONCLUSIONS: The 9-item ESFQ appears to be a valid measure to assess 
changes in eyelash-speciﬁc PROs. The factor structure showed near equivalence with 
the ESQ. Future research will involve further validation of the ESFQ in response to 
variations in hypotrichosis etiologies and clinical treatment paradigms.
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OBJECTIVES: Our objective was to compare the PRO endpoints recommended by 
the EMEA note for guidance on the clinical investigation of medicinal products 
indicated for the treatment of psoriasis (CHMP/EWP/2454/02) published in Novem-
ber 2004, with those used for the approval of medicinal products for psoriasis. 
METHODS: The EMEA website was searched to identify all medicinal products 
approved speciﬁcally for psoriasis since 1995. PROlabels was searched to identify 
the products with a PRO labeling claim. RESULTS: The EMEA guidance speciﬁes 
that “Patient-assessed drug efﬁcacy may be a secondary or tertiary endpoint in 
pivotal clinical trials. These measures correspond both to efﬁcacy evaluated by 
patients and to health-related quality of life (HRQL) scales validated in dermatol-
ogy”. The guidance quotes simple measures such as symptom improvement, tolerabil-
ity, cosmetic acceptability, ease of use, patient’s assessment of global improvement 
and more complex measures, such as the patient’s assessment of PASI, the Dermatol-
ogy Life Quality Index (DLQI), Dermatology Quality Life Scales (DQOLS), Skindex, 
Psoriasis Disability Index (PDI), and Psoriasis Life Stress Inventory (PLSI). Three 
products were retrieved; two approved before the publication of the guidance (2003, 
2004) and one after (2009). Methotrexate, cyclosporine and corticoids were not 
included for their lack of speciﬁcity. All three products had a PRO labeling claim. 
Improvement in the DLQI was used as a secondary endpoint in all products and 
quoted on the label. Itch was measured for 2 products (2004, 2009) by patient’s 
symptom measures and included on the label. Two products (2003, 2009) used the 
SF-36. CONCLUSIONS: There is a close adherence to the guidance concerning the 
choice of PRO endpoints. However, comparison of the dates of the guidance pub-
lication and of the products’ approval suggest that the guidance has only endorsed 
an existing practice in the choice of study endpoints for the evaluation of medicines 
indicated for psoriasis.
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OBJECTIVES: To assess the long-term impact of ustekinumab(UST) on quality of life 
(QoL) among patients responding to therapy at wk40. METHODS: In PHOENIX 1 
psoriasis patients were randomized to UST45 mg (n = 255), UST90 mg(n = 256), or 
placebo(n = 255). Placebo patients crossed over to receive UST45 mg or 90 mg at 
wk12. At wk40, UST PASI75 responders were re-randomized to continue the same 
dose of UST q12 wks or be withdrawn from treatment.After losing 50% of the 
improvement gained while on UST, patients withdrawn from treatment re-initiated 
UST at the same dose previously received.The DLQI assessed skin disease-speciﬁc QoL 
(lower scores indicating better QoL) through 3 yrs;change of >= 5 points was deﬁned 
as a clinically meaningful change and a score of 0/1 was deﬁned as no negative effect 
on patient’s life. RESULTS: 162 patients were re-randomized to UST at wk40 (n = 
77,45 mg; n = 85,90 mg); 320 patients were withdrawn from UST at wk40 (n = 
141,45 mg; n = 179,90 mg). Among patients re-randomized to UST, mean change 
from baseline in DLQI score for the 45 mg and 90 mg groups [mean(SD)] was: 
−9.1(7.0) and −10.0(6.1) at wk76 and −8.6(6.9) and −9.7(6.2) at Year3, respectively.
Among patients withdrawn, mean change from baseline in DLQI score for the 
UST45 mg and 90 mg groups [mean(SD)] was: −1.4(5.8) and −4.2(4.7) at wk76 and 
0.9(2.2) and −2.8(0.9) at Year3, respectively. At wk76 and Year3, 64.0% and 74.7%, 
and 64.6% and 65.4% of patients in the 45 mg and 90 mg groups,respectively,achieved 
a DLQI score of 0/1; at wks76 and Year3, 10.9% and 19.2%, and 3.1% and 13.9%, 
of patients withdrawn from 45 mg and 90 mg, respectively, achieved these results. In 
those re-randomized to UST, the proportion of patients in the 45 mg and 90 mg 
groups who experienced a ≥5 point improvement in DLQI was 73.3% and 78.5% at 
wk76, and 70.8% and 78.2% at Year3; in the withdrawal group, 19.6% and 20.9%, 
and 0.78% and 1.3%, of patients from 45 mg and 90 mg, respectively, achieved this 
result. CONCLUSIONS: Clinically meaningful QoL improvements are sustained 
through Year3 among patients responding at wk40 who continued to receive UST 
q12wks.
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OBJECTIVES: To evaluate the effect of adalimumab on health-related quality of life 
and patient-reported outcome (PRO) measures, including depression and health utility 
in patients with active plaque psoriasis. METHODS: PRIDE (A Canadian Open-Label 
Access PRogram to Evaluate the Safety and the Effectiveness of Adalimumab When 
Added to InaDEquate Therapy for the Treatment of Psoriasis) was an open-label, 
multicenter, Phase IIIb study in Canada. Patients with active moderate to severe plaque 
psoriasis who failed to respond to, or were intolerant of, prior therapies (photother-
apy, cyclosporine, methotrexate, and/or oral retinoids) received adalimumab (80 mg) 
at Week 0 followed by adalimumab (40 mg) every other week starting at Week 1. 
Changes in the Dermatology Life Quality Index (DLQI), Beck Depression Inventory-II 
(BDI) and EQ-5D at baseline, Week 16 and Week 24 were evaluated. RESULTS: A 
total of 203 patients (male, 61%; mean age, 46 years; mean PASI score, 20) were 
enrolled at 26 sites. At baseline, mean DLQI, BDI and EQ-5D were 12.9, 9.3, and 
0.79, respectively. At Week 16, the mean DLQI score had improved to 2.9 (change = 
10.0; p < 0.0001); the BDI was reduced to 5.2 (change = 4.2; p < 0.0001), and the 
EQ-5D had improved to 0.89 (change = 0.10; p < 0.0001). A 16-week results were 
sustained to 24-weeks, and all outcomes showed statistically signiﬁcant improvements 
from baseline. Improvements were even greater in patients with a baseline DLQI score 
>10. CONCLUSIONS: Adalimumab treatment was associated with statistically sig-
niﬁcant improvements in PROs of psoriasis patients in Canada, including depression. 
The results of this open-label study were consistent with outcomes observed in ran-
domized placebo controlled clinical trials of adalimumab, conﬁrming that adalimumab 
has a substantial impact on patient health-related quality of life.
